Due to the high morbidity and mortality rates, severe sepsis and septic shock, present a major global public health problem. The treatment and management of severe sepsis and septic shock is based on a set of international guidelines called the Surviving sepsis campaign (SSC). SSC guidelines suggest the use of hydrocortisone at a dose of 200 mg IV in adult patients with septic shock refractory to fluid resuscitation and vasopressors. During the last century, the importance of cortisol as an essential hormone at times of stress, such as septic shock, has been recognized. Therefore, the therapeutic use of synthetic glucocorticoids has been the subject of many studies during the last few decades but their results are not consistent. Two of the largest studies (CORTICUS and French study) showed different effects of synthetic glucocorticoids on mortality rates, but they both showed a significantly shorter duration of septic shock. There is an ongoing large, multicenter, doubleblind, randomized study (ADRENAL study) and its primary goal is to assess the impact of hydrocortisone therapy on 90-day survival rate. It is expected that the results of this study might provide answers to the questions raised by previously conducted studies. This review will summarize the pathophysiology of sepsis and septic shock and the role of cortisol in its development, and will highlight the most important clinical studies pertaining to synthetic glucocorticoid administration in sepsis and septic shock.
Introduction
The incidence of severe sepsis and septic shock is estimated to be between 56 to 91 per 100,000 population per year. Due to the high morbidity and mortality rates, sepsis and severe sepsis present a major global public health problem [1] . In their study in 2001, Rivers et al. [2] found that early goal-directed therapy (EGDT), a specific treatment in patients with sepsis, reduced mortality, and this was incorporated into the Surviving sepsis campaign (SSC), the international guidelines for the management of sepsis, severe sepsis, and septic shock [3] . These guidelines include specific procedures, monitoring, and treatment, which among other things include synthetic glucocorticoid therapy [3, 4] , as seen in Table 1 . The SSC recommends synthetic glucocorticoid therapy only in patients with septic shock in whom sepsis-induced hypotension persists despite adequate fluid resuscitation and vasopressor treatment (recommendation level 2C) [3] . The recommended dosage of intravenous hydrocortisone is 200 mg per day, and it is suggested that clinicians taper the dose of steroid therapy when vasopressors are no longer required. Synthetic glucocorticoid therapy and its effect on the course of septic shock has been the subject of many clinical studies. So far, studies have yielded inconclusive results, and their use in this clinical setting remains controversial.
The clinical course of sepsis
Sepsis is a clinical syndrome characterized by a systemic response to an infection. It is defined as the presence (probable or documented) of infection together with systemic manifestations of infection [4] . Criteria for sepsis diagnosis are: confirmed or suspected infection, and the presence of two or more criteria for the systemic inflammatory response syndrome (SIRS) that represents the response to an insult from either an infectious or noninfectious origin. Clinically, SIRS includes at least two of the following criteria: a) body temperature >38°C or <36°C, b) heart rate >90/ min, c) respiratory rate >20/min or PaCO2 <32 mmHg, d) leukocyte count >12,000 or <4,000 or >10% non-segmented leukocytes ( Table 2 ). Sepsis that results in tissue hypoperfusion or dysfunction of one or more organs is defined as severe sepsis [4] . Further worsening leads to septic shock, defined as sepsis-induced persistent hypotension (systolic blood pressure <90 mm Hg, mean arterial pressure <70 mmHg or reduction of systolic blood pressure >40 mmHg from baseline) despite adequate rehydration (Table 3, Table  4 ) [4] . Multi-organ dysfunction syndrome (MODS) is the most common cause of death in patients with severe sepsis, and it is defined as the presence of altered organ functions requiring medical intervention [5] . MODS develops due to the release and activation of pro-and anti-inflammatory cytokines, activation of the coagulation system, and the release of acute phase proteins and hormonal and neuronal mediators [6] [7] [8] . The immune response imbalance leads to leukocyte accumulation, disseminated intravascular coagulation, and the formation of intra-and extravascular fibrin clots. Coagulation factor consumption and platelet dysfunction leads to hemorrhagic diathesis, bleeding, microcirculatory dysfunction, and cellular hypoxic damage, resulting in necrosis of parenchymal cells and consequently to MODS (Table 4 .) [3, 7, [9] [10] [11] [12] [13] . Respiratory dysfunction manifests as acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), defined as the presence of acute non-cardiogenic pulmonary edema, absence of left atrium hypertension (PACP <18mmHg) and a hypoxemia ratio of PaO2/ FIO2 ≤300 (ALI) or ≤200 (ARDS). Acute tubular necrosis and the sudden and rapid decline in glomerular filtration leads to renal dysfunction and acute renal injury (ARI). Gastrointestinal tract dysfunction leads to bacterial translocation and translocation of digestive endotoxins and proteases into the systemic circulation that can cause paralytic ileus, stress ulcers, and bowel ischemia. Liver damage manifests as the reduced synthesis of acute phase proteins and coagulation cascade proteins, reticuloendothelial system dysfunction, increased liver enzymes, bilirubin, and ammonia, as well as hypotension, leading to central nervous system dysfunction, which can be manifested by quantitative and qualitative disorders of consciousness.
Cortisol in septic shock
The hypothalamic-pituitary-adrenal gland axis (HPA axis) is the main coordinator in the stress response. Corticotropin-releasing hormone (CRH) is released from the hypothalamus, which signals adrenocorticotropic hormone (ACTH) release from the pituitary with subsequent synthesis of cortisol from the adrenal cortex [14] . Cortisol is a hormone that is essential at times of stress, such as septic shock. Cortisol affects the synthesis and release of proand anti-inflammatory mediators, modifies monocytes in inflammatory conditions, raises the blood pressure by General variables Fever (> 38.3°C) Hypothermia (core temperature < 36°C) Heart rate > 90/min-1 or more than two SD above the normal value for age Tachypnea Altered mental status Significant edema or positive fluid balance (> 20 mL/kg over 24 h) Hyperglycemia (plasma glucose > 140 mg/dL or 7.7 mmol/L) in the absence of diabetes Inflammatory variables Leukocytosis (WBC count > 12,000 μL-1) Leukopenia (WBC count < 4000 μL-1) Normal WBC count with greater than 10% immature forms Plasma C-reactive protein more than two SD above the normal value Plasma procalcitonin more than two SD above the normal value increasing the reactivity of catecholamine receptors, and by favoring the extracellular space, affects the redistribution of body fluids [15, 16] . During physiological stress, the HPA axis is continuously activated causing the loss of diurnal cortisol secretion and resulting in elevated cortisol levels [17] [18] [19] [20] . In addition, the increase in blood cortisol levels during septic shock is a consequence of reduced cortisol metabolism, renal failure, increased peripheral resistance to cortisol, and reduced albumin and cortisol binding globulin levels, leading to higher free cortisol levels, the active form of the hormone [20] [21] [22] [23] .
Clinical significance of serum cortisol analysis
Many studies have been conducted trying to resolve why there is a big difference between serum cortisol levels in patients with septic shock, and whether there is a link between cortisol levels and mortality [24] [25] [26] [27] [28] [29] [30] . However, studies have shown conflicting results. While some studies found that lower serum cortisol levels were associated with increased mortality, others found that higher cortisol levels were associated with increased mortality, and some studies found no association [26, 28, [31] [32] [33] [34] [35] [36] . In one of these studies, a new theory of relative adrenal insufficiency was presented. It was based on an inadequate response or an inadequate increase in serum cortisol levels after a synthetic ACTH (cosyntropin) stimulation test, and it was thought that these patients could benefit from the hydrocortisone therapy [32] . However, the SSC does not recommend adrenal function assessment with ACTH stimulation tests in order assess the need for synthetic glucocorticoids in the case of relative adrenal insufficiency. This recommendation is based on recent studies that showed no statistically significant potential link between the use of cortisol and adrenal function, nor a difference in mortality in patients with or without relative adrenal insufficiency that were treated with hydrocortisone [37, 38] . As mentioned before, decreased cortisol binding globulin levels increase the level of free, active forms of cortisol. Therefore, free cortisol levels might better represent the activation of the hypothalamic-pituitary-adrenal gland in patients with hypoproteinemia. This was shown in a study of critically ill patients that had 2-3 times higher total serum cortisol levels in comparison to healthy individuals, and 7-10 times higher free cortisol levels [39] . However, in the cited study, patients with septic shock were not included and the level of hemodynamic instability at the time of sampling was not specified, and therefore the connection between cortisol levels with disease severity cannot be evaluated [40] . A subsequent study showed that patients with septic shock had higher free cortisol levels than patients with sepsis and healthy individuals, and free cortisol levels better correlated with disease severity than total cortisol levels [41] . The clinical application of these studies is questionable because analysis of free cortisol levels is not available in most centers around the world.
Synthetic glucocorticoid therapy in the past
Throughout history, a number of studies have been performed on the therapeutic use of synthetic glucocorticoids in septic shock. Even in the first half of the 20th century, the importance of the adrenal glands in the protection of the body against bacterial infections was recognized, and later, with the discovery of cortisone, the clinical use of synthetic glucocorticoids in the treatment of infectious conditions began [42] [43] [44] [45] [46] [47] . In 1976, Schumer presented a study that showed reduced mortality in patients with septic shock treated with methylprednisolone [48] . After this study, methylprednisolone at a dose of 30 mg/kg became a standard part of septic shock treatment. However, studies conducted in the eighties investigating the use of high-dose synthetic glucocorticoid therapy did not show lower mortality rates in patients treated with methylprednisolone, but instead they showed an increase in morbidity due to secondary infections [49] [50] [51] . During the nineties, several smaller studies compared the effects of placebo and lower doses of hydrocortisone (200-400 mg per day) in patients with septic shock. The results showed that patients treated with hydrocortisone had a higher survival rate and faster reversal of septic shock [52, 53] . In 2002, a larger multicenter study (French study), involving 300 patients with septic shock, was conducted in 19 intensive care units in France [37] . The ACTH stimulation test was performed with 250 mg cosyntropin and depending on the results, the patients were divided into two groups: patients with relative adrenal insufficiency (non-responders) defined as an increase of total cortisol ≤9 mg/dL after stimulation, and patients with normal adrenal function [37] . Comparing the placebo effect with the effect of hydrocortisone and fludrocortisone in lower doses, patients were randomly assigned to receive either hydrocortisone (50-mg intravenous bolus every 6 hours) and fludrocortisone (50-µg tablet once daily) (n = 151) or matching placebos (n = 149) for 7 days. Annan and colleagues came to the conclusion that the group of patients who received corticosteroids had lower mortality and a shortened need for vasopressor therapy ( Figure 1 ) [37] . In addition, no significant difference in the rate of side effects was found.
The next large multicenter study was The Corticosteroid Therapy of Septic Shock study (CORTICUS), which included 499 patients with septic shock who received placebo or hydrocortisone in a total dose of 200 mg per day [38] . The drugs were administered as a 50-mg intravenous bolus every 6 hours for 5 days, then tapered to 50 mg intravenously every 12 hours for days 6 to 8, 50 mg every 24 hours for days 9 to 11, and then stopped. Patients were divided into two groups: patients with relative adrenal insufficiency and patients with normal adrenal function. In both groups, patients receiving hydrocortisone did not have a decrease in mortality rates compared to patients who received placebo. However, this study also demonstrated the beneficial role of hydrocortisone on shortening the duration of septic shock ( Figure 2 ) [38] .
The different results regarding mortality rates in these two studies could be explained by the difference in their methodology. Patients in the French study had higher Simplified Acute Physiology Score II (SAPS II) than those in the CORTICUS study. In the French study, septic shock was defined as a systolic blood pressure <90 mmHg for more than one hour despite adequate fluid resuscitation and vasopressor administration, and in CORTICUS as a systolic blood pressure <90 mmHg despite adequate fluid resuscitation, or the need for vasopressor administration for more than one hour. Furthermore, the duration of hydrocortisone treatment was shorter in the CORTICUS study (5 days vs. 7 days, in the French study) and fludrocortisone was not used. Despite these differences, the results of both studies showed that hydrocortisone therapy reverses septic shock quicker, and subsequent analysis of data from the CORTICUS study showed that patients achieved more rapid hemodynamic stability and possibly faster recovery of renal function [54] .
Since the publication of the above-mentioned studies, several meta-analyses including studies published from January 1993 to December 2008, were performed. The results showed that the treatment of septic shock with synthetic glucocorticoids significantly shortens the duration of septic shock but does not reduce the 28-day mortality [55, 56] . It should also be noted that the results were independent of adrenal gland function. Currently, there is an ongoing multicenter, double-blind, randomized study Adjunctive Corticosteroid Treatment in Critically Ill Patients with Septic Shock (ADRENAL) [57] . The study began in June 2012 and its completion is expected in June 2016. It is being conducted in centers in Australia, New Zealand, Saudi Arabia, the United Kingdom, and Denmark. It includes 3800 patients with vasopressor dependent septic shock, and its primary goal is to assess the impact of hydrocortisone therapy at a daily dose of 200 mg on 90-day survival rate. Since it is a large multicenter study, it is expected that the results could provide answers to many questions raised with previously conducted studies.
Conclusion
Due to the high morbidity and mortality, sepsis, severe sepsis, and septic shock are an important global public health problem. Treatment recommendations have changed over the years, and one controversial issue that has remained is the use of synthetic glucocorticoids. Over the years, numerous studies have been conducted, investigating the role of synthetic glucocorticoids in septic shock; however, the results have been inconsistent. For now, the risk-benefit ratio of synthetic glucocorticoids remains unclear. In most of the world, the therapeutic approach for sepsis follows the SSC guidelines, which, for now, suggest the use of hydrocortisone at a dose of 200 mg IV in adult patients with septic shock refractory to fluids resuscitation and vasopressors. Although synthetic glucocorticoids may accelerate the recovery of unstable patients, one should always keep their severe side effects in mind. Therefore, the clinician must play a central role in the decisions-making process and assess the advantages and disadvantages of synthetic glucocorticoids in each patient individually.
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